Taylor Williams, 17, of Wixom, Mich., has suffered from severe headaches for more than two years. The headaches, which caused Taylor to seek medical treatment including emergency care on a number of occasions, were continuous and the medications prescribed were not working.

Pfizer Inc. announced that the co-primary clinical endpoints, change in cognitive and functional performance compared to a placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer’s disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 301). Pfizer and Janssen AI are partners in the Alzheimer’s Immunotherapy Program (AIP).

Genzyme , a Sanofi company announced that the company has submitted a supplemental Biologics License Application ( sBLA ) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application ( MAA ) to the European Medicines Agency ( EMA ) seeking approval of LEMTRADA ( alemtuzumab ) for treatment of relapsing multiple sclerosis ( RMS ).

Pfizer Inc. announced that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer’s disease who carry the ApoE4 ( apolipoprotein E epsilon 4) genotype (Study 302).

Pfizer Inc. announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for postmenopausal women with a uterus for the treatment of estrogen deficiency symptoms and treatment of osteoporosis in women at risk of fracture.

Pfizer Inc. announced that it has received a Complete Response Letter from the US Food and Drug Administration (FDA) on its New Drug Application (NDA) for tafamidis meglumine .

Pfizer Inc. announced that it has stopped a Phase 3 clinical trial of Lyrica ( pregabalin ) in patients with neuropathic pain associated with HIV neuropathy, a form of nerve damage characterized by burning pain usually beginning in the feet.

Pfizer Inc. announced that a Phase 3 randomized withdrawal design study for Lyrica ( pregabalin ) in patients with inadequately treated painful diabetic peripheral neuropathy ( pDPN ) did not meet its primary efficacy endpoint.

Abbott announced the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel ( LCIG ).

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tafamidis meglumine , the company’s investigational, novel, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy ( TTR-FAP ).